Synthesis and biological investigation of coumarin piperazine (piperidine) derivatives as potential multireceptor atypical antipsychotics

Journal of Medicinal Chemistry

Volumn 56, Issue 11, 2013, Pages 4671-4690

  Chen, Yin ^a,b   Wang, Songlin ^a   Xu, Xiangqing ^b   Liu, Xin ^a   Yu, Minquan ^b   Zhao, Song ^b   Liu, Shicheng ^b   Qiu, Yinli ^b   Zhang, Tan ^b   Liu, Bi Feng ^a   Zhang, Guisen ^a,b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Jiangsu Nhwa Pharmaceutical Co Ltd   (China)

Author keywords

[No Author keywords available]

Indexed keywords

7 [4 [4 [6 FLUOROBENZO(D)ISOXAZOL 3 YL] PIPERIDIN 1 Y]BUTOXY] 4 METHYL 8 CHLORO 2H CHROMEN 2 ONE; APOMORPHINE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; COUMARIN DERIVATIVE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; HALOPERIDOL; PIPERAZINE DERIVATIVE; PROLACTIN; RISPERIDONE; SEROTONIN 2A RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; AVOIDANCE BEHAVIOR; CLIMBING; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SAFETY; DRUG SYNTHESIS; HYPERACTIVITY; LD 50; MOUSE; NONHUMAN; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE; STRUCTURE ACTIVITY RELATION; WEIGHT GAIN;

ANIMALS; ANTIPSYCHOTIC AGENTS; AVOIDANCE LEARNING; BIOLOGICAL AVAILABILITY; COUMARINS; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; ISOXAZOLES; LETHAL DOSE 50; MICE; MOTOR ACTIVITY; PROLACTIN; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; STRUCTURE-ACTIVITY RELATIONSHIP; WEIGHT GAIN;

EID: 84879065940     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400408r     Document Type: Article

References (64)

1. Ibrahim, H. M.; Tamminga, C. A. Schizophrenia: treatment targets beyond monoamine systems Annu. Rev. Pharmacol. Toxicol. 2011, 51, 189-209
2. Lewine, R. R. J.; Fogg, L.; Meltzer, H. Y. Assessment of negative and positive symptoms in schizophrenia Schizophr. Bull. 1983, 9, 368-376
3. Marde, S. R.; Wirshing, W. C.; Van Putten, T. Drug treatment of schizophrenia. Overview of recent research Schizophr. Res. 1991, 4, 81-90
4. Baldessarini, R. J.; Tarsy, D. Dopamine and the pathophysiology of dyskinesias induced by antipsychotic drugs Annu. Rev. Neurosci. 1980, 3, 23-41
5. Boyd, A. E.; Reichlin, S. Neural control of prolactin secretion in man Psychoneuroendocrinology 1978, 3, 113-130 (Pubitemid 9010369)
6. Geddes, J.; Freemantle, N.; Harrison, P.; Bebbington, P. Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis BMJ 2000, 321, 1371-1376
7. Jones, C. A.; McCreary, A. C. Serotonergic approaches in the development of novel antipsychotics Neuropharmacology 2008, 55, 1056-1063
8. Shapiro, D.; Renock, S.; Arrington, E.; Chiodo, L.; Liu, L. Aripiprazole: a novel atypical antipsychotic drug with a unique and robust pharmacology Neuropsychopharmacology 2003, 28, 1400-1411 (Pubitemid 41070874)
9. Roth, B. L.; Hanizavareh, S. M.; Blum, A. E. Serotonin receptors represent highly avorable molecular targets for cognitive enhancement in schizophrenia and other disorders Psychopharmacology 2004, 174, 17-24 (Pubitemid 38925086)
10. Meltzer, H. Y.; Li, Z.; Kaneda, Y.; Ichikawa, J. Serotonin receptors: their key role in drugs to treat schizophrenia Prog. Neuro-psychopharmacol. Biol. Psychiatry 2003, 27, 1159-1172 (Pubitemid 37464960)
11. Kinon, B. J; Liberman, J. A. Mechanisms of action of atypicalantipsychotic drugs: a critical analysis Psychopharmacology 1996, 124, 2-34 (Pubitemid 26111436)
12. Moller, H. J. Management of the negative symptoms of schizophrenia: new treatment options CNS Drugs 2003, 17, 793-823
13. Vohora, D. Atypical antipsychotic drugs: current issues of safety and efficacy in the management of schizophrenia Curr. Opin. Invest. Drugs 2007, 8, 531-538 (Pubitemid 47016321)
14. Schultz, S. H.; North, S. W.; Shields, C. G. Schizophrenia: a review Am. Fam. Physician 2007, 75, 1821-1829 (Pubitemid 46954070)
15. Meltzer, H. Y. What's atypical about atypical antipsychotic drugs? Curr. Opin. Pharmacol. 2004, 4, 53-57 (Pubitemid 38145838)
16. Morphy, R.; Rankovic, Z. Designing multiple ligands-medicinal chemistry strategies and challenges Curr. Pharm. Des. 2009, 15, 587-600
17. Wong, E. H.; Tarazi, F. I.; Shahid, M. The effectiveness of multi-target agents in schizophrenia and mood disorders: Relevance of receptor signature to clinical action Pharmacol. Ther. 2010, 126, 173-185
18. 6 receptors in learning and memory Trends Pharmacol. Sci. 2008, 29, 482-492
19. 1A receptors in learning and memory Behav. Brain Res. 2008, 195, 54-77
20. Nichols, D. E.; Nichols, C. D. Serotonin receptors Chem. Rev. 2008, 108, 1614-1641 (Pubitemid 351796401)
21. Lameh, J.; Burstein, E. S; Taylor, E.; Weiner, D. M; Vanover, K. E; Bonhaus, D. W. Pharmacology of N-desmethylclozapine Pharmacol. Ther. 2007, 115, 223-231 (Pubitemid 47042913)
22. 2A receptors: Design, synthesis, and effects on behavior J. Med. Chem. 2009, 52, 151-169
23. Kim, D. H.; Stahl, S. M. Antipsychotic drug development Curr. Top. Behav. Neurosci. 2010, 4, 123-139
24. Meltzer, H. Y.; Matsubara, S.; Lee, M. A. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin 2 pKi values J. Pharmacol. Exp. Ther. 1989, 251, 238-246
25. Zhang, A.; Neumeyer, J. L.; Baldessarini, R. J. Recent progress in development of dopamine receptor subtype-selective agents: potential therapeutics for neurological and psychiatric disorders Chem. Rev. 2007, 107, 274-302 (Pubitemid 46237370)
26. Sibley, D. R.; Monsma, F. J., Jr.; Shen, Y. Molecular neurobiology of dopaminergic receptors Int. Rev. Neurobiol. 1993, 35, 391-415
27. Sealfon, S. C.; Olanow, C. W. Dopamine receptors: from structure to behavior Trends Neurosci. 2000, 23, S34-S40
28. 3 receptor mediates locomotor hyperactivity induced by NMDA receptor blockade Neuropharmacology 2003, 45, 174-181 (Pubitemid 36782530)
29. Reavill, C.; Taylor, S. G.; Wood, M. D.; Ashmeade, T.; Austin, N. E.; Avenell, K. Y.; Boyfield, I.; Branch, C. L.; Cilia, J.; Coldwell, M. C.; Hadley, M. S.; Hunter, A. J.; Jeffrey, P.; Jewitt, F.; Johnson, C. N.; Jones, D. N.; Medhurst, A. D.; Middlemiss, D. N.; Nash, D. J.; Riley, G. J.; Routledge, C.; Stemp, G.; Thewlis, K. M.; Trail, B.; Vong, A. K.; Hagan, J. J. Pharmacological actions of a novel, high-affinity, and selective human dopamine D3 receptor antagonist, SB-277011-A J. Pharmacol. Exp. Ther. 2000, 294, 1154-1165 (Pubitemid 30666872)
30. 3 dopamine receptor, behavioral sensitization, and psychosis Neurosci. Biobehav. Rev. 2001, 5, 427-443 (Pubitemid 32879299)
31. 3 receptor antagonists improve the learning performance in memory-impaired rats Psychopharmacology 2005, 179, 567-575 (Pubitemid 40674757)
32. Meltzer, H. Y. Cognitive factors in schizophrenia: causes, impact, and treatment CNS Spectrosc. 2004, 9, 15-24 (Pubitemid 39473435)
33. 3 receptor function Nat. Med. 2003, 9, 762-767 (Pubitemid 36749227)
34. 2 receptor antagonist and potential antipsychotic agent: III. Actions in models of therapeutic activity and induction of side effects J. Pharmacol. Exp. Ther. 2008, 324, 1212-1226 (Pubitemid 351397860)
35. 1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs Neuropsychopharmacology 2003, 28, 519-526
36. 1 receptor-linked activation of hypothalamic AMP-kinase Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 3456-3459 (Pubitemid 46364180)
37. 2C receptor antagonist Br. J. Pharmacol. 1999, 126, 572-574 (Pubitemid 29087833)
38. 2C receptor inverse agonist with improved anxiolytic profile: Lack of tolerance and withdrawal anxiety Neuropharmacology 2001, 41, 186-199 (Pubitemid 32728090)
39. 2C receptor gene with antipsychotic-induced weight gain Am. J. Psychiatry 2005, 162, 613-615 (Pubitemid 40343933)
40. 2C receptor and antipsychotic induced weight gain-mechanisms and genetics J. Psychopharmacol. 2006, 20, 15-18 (Pubitemid 44576653)
41. Garzya, V.; Forbes, I. T.; Gribble, A. D.; Hadley, M. S.; Lightfoot, A. P. Studies towards the identification of a new generation of atypical antipsychotic agents Bioorg. Med. Chem. Lett. 2007, 17, 400-405 (Pubitemid 46073754)
42. Ablordeppey, S. Y.; Altundas, R.; Bricker, B.; Zhu, X. Y.; Kumar, E. V.; Jackson, T.; Khan, A.; Roth, B. L. Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-Chlorophenyl)-1,4-diazepan-1- yl]-1-(4-fluorophenyl)butan-1-one Bioorg. Med. Chem. 2008, 16, 7291-7301
43. 1A receptors Bioorg. Med. Chem. 2010, 18, 1925-1935
44. Chen, Y.; Xu, X. Q.; Liu, X.; Yu, M. Q.; Liu, B. F.; Zhang, G. S. Synthesis and evaluation of a series of 2-substituted-5-thiopropylpiperazine (piperidine)-1,3,4-oxadiazoles derivatives as atypical antipsychotics PLoS One 2012, 7, e35186
45. 2A receptors Bioorg. Med. Chem. Lett. 2003, 13, 175-178 (Pubitemid 35446319)
46. 3 receptors Bioorg. Med. Chem. Lett. 1998, 8, 3567-3570 (Pubitemid 29012578)
47. Pisani, L.; Muncipinto, G.; Miscioscia, T. F.; Nicolotti, O.; Leonetti, F.; Catto, M.; Caccia, C.; Salvati, P.; Soto-Otero, R.; Mendez-Alvarez, E.; Passeleu, C.; Carotti, A. Discovery of a novel class of potent coumarin monoamine oxidase B inhibitors: Development and biopharmacological profiling of 7-[(3-chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one methanesulfonate (NW-1772) as a highly potent, selective, reversible, and orally activemonoamine oxidase B inhibitor J. Med. Chem. 2009, 52, 6685-6706
48. Zhou, Z.; Fahrni, C. J. A fluorogenic probe for the copper (I)-catalyzed azide-alkyne ligation reaction: modulation of the fluorescence emission via MO inversion J. Am. Chem. Soc. 2004, 126, 8862-8863 (Pubitemid 38971037)
49. Singh, I.; Prasad, A. K.; Sharma, A. K.; Saxena, R. K.; Olsen, C. E.; Cholli, A. L.; Samuelson, L. A.; Kumar, J.; Watterson, A. C.; Parmar, V. S. Synthetic and novel biocatalytic resolution studies on (±)-5/6/7-acetoxy- 4-aryl-3,4-dihydrocoumarins Bioorg. Med. Chem. 2003, 11, 529-538 (Pubitemid 36132230)
50. 2A receptors Eur. J. Med. Chem. 2002, 37, 503-510 (Pubitemid 35245173)
51. Lepor, H.; Jones, K.; Williford, W. The mechanism of adverse events associated with terazosin: An analysis of the Veterans Affairs cooperative study J. Urol. 2000, 163, 1134-1137 (Pubitemid 30169378)
52. Takata, Y.; Kurihara, J.; Suzuki, S.; Okubo, Y.; Kato, H. A rabbit model forevaluation of chlorpromazine-induced orthostatic hypotension Biol. Pharm. Bull. 1999, 22, 457-462 (Pubitemid 29252217)
53. 2 adrenoceptor blockade Science 1999, 286, 105-107 (Pubitemid 29484485)
54. Recanatini, M.; Poluzzi, E.; Masetti, M.; Cavalli, A.; De, P. F. QT prolongation through hERG K (+) channel blockade: current knowledge and strategies for the early prediction during drug development Med. Res. Rev. 2005, 25, 133-166 (Pubitemid 40299844)
55. Kim, H. S.; Rhee, G. S.; Oh, S.; Park, W. K. NMDA receptor antagonists inhibit apomorphine-induced climbing behavior not only in intact mice but also in reserpine-treated mice Behav. Brain Res. 1999, 100, 135-142 (Pubitemid 29130247)
56. Campiani, G.; Butini, S.; Fattorusso, C.; Catalanotti, B.; Gemma, S.; Nacci, V.; Morelli, E.; Cagnotto, A.; Mereghetti, I.; Mennini, T.; Carli, M.; Minetti, P.; Di Cesare, M. A.; Mastroianni, D.; Scafetta, N.; Galletti, B.; Stasi, M. A.; Castorina, M.; Pacifici, L.; Vertechy, M.; Di Serio, S.; Ghirardi, O.; Tinti, O.; Carminati, P. Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents J. Med. Chem. 2004, 47, 143-157 (Pubitemid 38040498)
57. 2 dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia Br. J. Psychiatry 2001, 179, 503-508 (Pubitemid 34031674)
58. Yee, S. W.; Shah, B.; Simons, C. Synthesis and antimycobacterial activity of 7-O-substituted-4-methyl-2H-2-chromenone derivatives vs Mycobacterium tuberculosis J. Enzyme Inhib. Med. Chem. 2005, 20, 109-113 (Pubitemid 40645500)
59. Frecentese, F.; Fiorino, F.; Perissutti, E.; Severino, B.; Magli, E. Efficient microwave combinatorial synthesis of novel indolic arylpiperazine derivatives as serotoninergic ligands Eur. J. Med. Chem. 2010, 45, 752-759
60. 3H]-mepyramine binding sites in guinea pig cerebellum and lung Agents Actions 1991, 33, 181-184
61. 1A serotoninergic receptors Bioorg. Med. Chem. 2006, 14, 2828-2836 (Pubitemid 43343670)
62. Roche, O.; Trube, G.; Zuegge, J. A virtual screening method for prediction of the hERG potassium channel liability of compound libraries ChemBioChem 2002, 3, 455-459 (Pubitemid 36002290)
63. 2C receptors in CHO-K1 cells Br. J. Pharmacol. 1999, 128, 13-20 (Pubitemid 29425262)
64. 16 couple a wide variety of receptors to phospholipase C J. Biol. Chem. 1995, 270, 15175-15180